Aug 1, 1999 · DepoCyt (Cytarabine Liposomal) Injection Company: DepoTech Corporation Application No.: 21-041 Approval Date: 8/1/1999 Approval Letter (s) (PDF) Medical Review (s) (PDF) Chemistry …

Liposomal cytarabine is FDA approved for the treatment of lymphomatous meningitis, which is lymphoma that is present in the meninges (lining of the brain and spinal cord). Liposomal cytarabine …

DepoCyt package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.

Dec 1, 1998 · SILVER SPRING, Md-Depo-Tech’s DepoCyt (cytarabine liposome injection) has won the backing of the Oncology Drug Advisory Committee (ODAC), which recommended that the FDA grant …

DepoCyt is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat certain types of leukemia and lymphoma that have spread to the meninges – the layers of tissue that …

List of Approved Drug Products containing Depocyt in the FDA Orange Book on PharmaCompass.com

Dec 2, 1996 · - DepoTech has begun the filing of its New Drug Application with the US Food and Drug Administration for its anticancer agent DepoCyt (sustained-release cytarabine) for patients with …

DepoCyt® (cytarabine liposome injection) is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt is a cytotoxic anticancer drug and, as with other potentially toxic...

Apr 20, 2007 · Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that the US Food and Drug Administration (FDA) has granted full approval for DepoCyt ® (cytarabine liposome injection) …

2007-04-19: Converted to regular approval for intrathecal treatment of lymphomatous meningitis. 2011-08-11 (oldest label available at Drugs @ FDA): indicated for the intrathecal treatment of …